Discover and read the best of Twitter Threads about #Angrez
Most recents (3)
India's far-Right Internet warriors are so quick to jump on the desi v Amreeka bandwagon. This @Twitter exchange is being shared on Whatsapp groups with comments s/as: "Typical mentality that keeps us enslaved psychologically". 
The US FDA's action might seem arbitrary, and Pfizer's demands may well seem arrogant, but to link the two in some kind of #Bharat as #Vishwaguru v America as Foreign #Angrez #Gora bad guy is silly, unhelpful, and won't get us anywhere. There are two questions that are relevant
Q1. Is the @US_FDA singling out @BharatBiotech's Covaxin for discriminatory treatment because it is a #desi #vaccine?. BTW, that is not my descriptive term it was used by @blsanthosh.
A. No. Not if you consider that so far ONLY 3 vaccines have had #EUA from the FDA.
A. No. Not if you consider that so far ONLY 3 vaccines have had #EUA from the FDA.
I actually have sympathy for @BharatBiotech's scientists and the volunteers who took part in their clinical trials so far. They have been let down by bad science and poor regulatory processes. The company should never have submitted #Covaxin for regulatory approval w/o Ph 3 data
That mistake -the original sin, if you like- has led to a series of mis-steps, errors, cover-ups, linguistic contortions, and lack of clarity. The regulator shd have held the #Covaxin approval request and said, "we'll look at it when you have at least some preliminary ph 3 data"
Instead, they clubbed their approval of 3 separate products into one press release. That was Mistake No 3, driven I suspect by the desire to have a wholly Indian offering (Covishield though made in Pune was already labelled, don't forget as an #Angrez product.
The shambles and confusion about the regulatory approval for @BharatBiotech's #Covishield #vaccine will have serious consequences for the #Indian #biopharma industry. The real tragedy is NOT that an unsuitable or ineffective vaccine has been approved.
The real tragedy has been that the scientific process of basing decisions on data has been ruptured. Today nobody has any idea of the efficacy (as judged in field trials) of the efficacy of #Covaxin. This is as much a slap in the face for the scientists in @BharatBiotech
as it is a betrayal of the 22,000 subjects who had been enrolled in the as yet on-going phase 3 clinical trials. Their altruism in volunteering for the trial has been trashed, as has the painstaking work of the trial doctors been devalued.
